Truvian Partnered With Siemens Healthineers on Diagnostics
Diagnostic providers will gain support in scaling the TruVerus platform across clinics and pharmacies.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Would you prefer to have routine diagnostic blood tests done at a local pharmacy?
Truvian has entered a strategic partnership with Siemens Healthineers to accelerate the market adoption of its TruVerus diagnostic system. The collaboration will leverage Siemens' global commercial infrastructure to place the testing platform into health systems, retail pharmacies, and clinical research sites.
Why it matters
The deal aims to scale patient access to rapid diagnostic testing by combining Truvian's point-of-care technology with the established commercial reach of a major global diagnostics player. It marks a push to move specialized testing capabilities closer to the point of care, reducing the dependency on centralized labs.
The TruVerus system provides results in approximately 30 minutes and has received FDA clearance for complete blood counts plus nine metabolic, cardiovascular, and liver health analyses. Financial terms of the agreement between the two firms were not disclosed.
The players
Truvian
A medical device developer focused on automated, rapid diagnostic testing hardware and single-use reagent technology.
Siemens Healthineers
A global leader in medical technology and diagnostics that provides commercial infrastructure and technical support to healthcare providers.
The details
The TruVerus platform integrates a cell imager, absorbance reader, bead scanner, automated pipettor, and onboard centrifuge to process blood samples via single-use reagent kits. Siemens Healthineers will support this hardware deployment by providing technical resources and commercial guidance. This operational support is designed to facilitate the platform's integration into diverse clinical environments, including doctors' offices and retail pharmacy locations.
Timeline
December 2025: The FDA cleared the TruVerus instrument and a kidney panel.
January 2026: The FDA cleared complete blood counts and nine additional metabolic, cardiovascular, and liver health analyses.
October 2026: Truvian and Siemens Healthineers announced their partnership.
Market Landscape
This partnership follows the successful completion of FDA 510(k) clearance protocols for the TruVerus platform, marking a transition from regulatory validation to commercial expansion. The deal reflects a broader trend of large medical technology firms partnering with startups to bridge the gap between niche diagnostic innovation and large-scale clinical distribution.
Operators in clinical settings should monitor how the deployment of the TruVerus system affects patient throughput and diagnostic service revenue. The increased availability of rapid testing in retail and primary care may necessitate adjustments to existing procurement strategies for diagnostic reagents and equipment.
The takeaway
The partnership validates a push for rapid, near-patient diagnostic testing as a standard service model. Operators should track the platform's rollout into retail and primary care settings to assess the potential impact on their own lab testing volumes and patient retention strategies.
Further reading
For more information on diagnostic technology trends, visit the Healthcare section.
Live Poll
Would you prefer to have routine diagnostic blood tests done at a local pharmacy?
